Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Holdings Increased by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. raised its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 46.7% during the 4th quarter, Holdings Channel reports. The fund owned 24,625 shares of the medical research company’s stock after purchasing an additional 7,837 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Bio-Rad Laboratories were worth $8,090,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Bio-Rad Laboratories by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company’s stock worth $630,676,000 after purchasing an additional 12,168 shares during the period. Wealthfront Advisers LLC purchased a new position in Bio-Rad Laboratories in the fourth quarter valued at about $342,686,000. Dimensional Fund Advisors LP lifted its position in shares of Bio-Rad Laboratories by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company’s stock worth $245,106,000 after buying an additional 91,690 shares during the last quarter. Earnest Partners LLC lifted its position in shares of Bio-Rad Laboratories by 2.1% in the fourth quarter. Earnest Partners LLC now owns 618,049 shares of the medical research company’s stock worth $203,035,000 after buying an additional 12,500 shares during the last quarter. Finally, Ariel Investments LLC lifted its position in shares of Bio-Rad Laboratories by 48.0% in the fourth quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company’s stock worth $184,138,000 after buying an additional 181,829 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Up 2.5%

Shares of Bio-Rad Laboratories stock opened at $242.94 on Friday. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99. The business has a fifty day simple moving average of $243.51 and a 200 day simple moving average of $299.31. The stock has a market cap of $6.80 billion, a PE ratio of -3.74 and a beta of 1.00.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to analysts’ expectations of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The firm’s quarterly revenue was down 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.30 earnings per share. Research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BIO. UBS Group decreased their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, February 17th. Wells Fargo & Company dropped their target price on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Royal Bank of Canada cut their price objective on Bio-Rad Laboratories from $409.00 to $392.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Finally, Citigroup cut their price objective on Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $327.40.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.